Carbapenem stewardship: Does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence

International Journal of Antimicrobial Agents

Volumn 39, Issue 1, 2012, Pages 11-15

  Nicolau, David P ^a   Carmeli, Yehuda ^b   Crank, Christopher W ^c   Goff, Debra A ^d   Graber, Christopher J ^e   Lima, Ana Lucia L ^f   Goldstein, Ellie J C ^e,g  

^a HARTFORD HOSPITAL   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

Carbapenem; Ecology; Ertapenem; Pseudomonas; Stewardship; Susceptibility

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG FORMULARY; DRUG UTILIZATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; TEACHING HOSPITAL;

EID: 82955187653     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.08.018     Document Type: Short Survey

References (19)

1. D. Weber Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management Int J Infect Dis 10 Suppl. 2 2005 S17 S24
2. J. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, and C.D. Martin International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2009 2323 2329
3. R. Pires dos Santos, T. Jacoby, and L. Zubaran Goldani Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance? Antimicrob Agents Chemother 54 2010 3076 3077
4. D. Paterson 'Collateral damage' from cephalosporin or quinolone antibiotic therapy Clin Infect Dis 38 Suppl. 4 2004 S341 S345
5. D. Paterson, and R.A. Bonomo Extended-spectrum β-lactamases: a clinical update Clin Microbiol Rev 18 2005 657 686
6. E. Goldstein, D.M. Citron, V. Peraino, T. Elgourt, A.R. Meibohm, and S. Lu Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa Antimicrob Agents Chemother 53 2009 5122 5126
7. D. Goff, and J.E. Mangino Ertapenem: no effect on aerobic Gram-negative susceptibilities to imipenem J Infect 57 2008 123 127
8. K. Eagye, and D.P. Nicolau Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals Infect Control Hosp Epidemiol 31 2010 485 490
9. K.J. Eagye, and D.P. Nicolau Change in anti-pseudomonal carbapenem susceptibility in 25 hospitals over 9 years is not associated with the use of ertapenem J Antimicrob Chemother 66 2011 1392 1395
10. A. Lima, P.R. Oliveira, A.P. Paula, K. Dal-Paz, F. Rossi, and A. Zumiotti The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study Infect Control Hosp Epidemiol 30 2009 487 490
11. A. Lima, P.R.D. Oliveira, A.P. Paula, and A. Zumiotti Influence of ertapenem administration on the incidence of carbapenem-resistant Pseudomonas aeruginosa Braz J Infect Dis 12 2008 105 106
12. A. Lima, P.R. Oliveira, A.P. de Paula, K. Dal-Paz, J.N. de Almeida Jr., and C. da Sliva Felix Carbapenem stewardship: positive impact on hospital ecology Braz J Infect Dis 15 2011 1 5
13. C. Crank, B. Hota, and J. Segreti Effect of ertapenem utilization on Pseudomonas aeruginosa susceptibility to imipenem 44th annual meeting of the Infectious Diseases Society of America 12-15 October 2006, Toronto, Canada 2006 IDSA Arlington, CA [Poster 285]
14. D. Goff, and J.E. Mangino Effect of ertapenem on susceptibility of imipenem to Pseudomonas aeruginosa six years later 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 10-13 April 2010, Vienna, Austria 2010 ESCMID Basel, Switzerland [Abstract O482]
15. Y. Carmeli, S. Klarfeld Lidji, S. Navon-Venezia, and M.J. Schwaber The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study Diagn Microbiol Infect Dis 70 2011 367 372
16. C.J. Graber, C. Hutchings, F. Dong, W. Lee, J.K. Chung, and T. Tran Changes in antibiotic usage and susceptibility among nosocomial Enterobacteriaceae and Pseudomonas isolates following the introduction of ertapenem to hospital formulary Epidemiol Infect 2011 1 11 10.1017/ S0950268811000082 [Epub ahead of print]
17. M. DiNubile, I. Friedland, C.Y. Chan, M.R. Motyl, H. Giezek, and M. Shivaprakash Bowel colonization with resistant Gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy Eur J Clin Microbiol Infect Dis 24 2005 443 449 (Pubitemid 41124495)
18. M.J. DiNubile, J.W. Chow, V. Satishchandran, A. Polis, M.R. Motyl, and M.A. Abramson Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections Antimicrob Agents Chemother 49 2005 3127 3221
19. Y. Carmeli Strategies for managing today's infections Clin Microbiol Infect Dis 14 Suppl. 3 2010 22 31